STOCK TITAN

Sensus Healthcare to Host First Quarter 2022 Financial Results and Business Update Conference Call on May 5, 2022

(Neutral)
(Neutral)
Tags
conferences earnings date

Rhea-AI Summary

Sensus Healthcare, Inc. (Nasdaq: SRTS) has announced a conference call scheduled for May 5, 2022, at 4:30 p.m. Eastern time to discuss its financial results for Q1 2022. The call will also include a business update covering recent and upcoming milestones. Investors can access the call via dial-in numbers or through a live webcast on the company's website. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, utilizing low-energy X-ray technology for various medical applications.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction – SRTS

-4.92%
-4.92% Session move

In the trading session that priced this news, SRTS declined 4.92%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

BOCA RATON, Fla, April 21, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 5, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

To access the conference call, the dial-in numbers are 888-390-3967 (U.S. and Canada Toll Free), 862-298-0702 (International). Please direct the operator to be connected to the Sensus Healthcare conference call. The call will be webcast live and can be accessed at the following link, which also may be found in the Investor Relations section of the Company’s website at www.sensushealthcare.com.

Following the conclusion of the conference call, a replay will be available and can be accessed by dialing 888-539-4649 (U.S. and Canada Toll Free), or 754-333-7735 (International).  At the system prompt, dial the replay code – 157081 followed by the # sign. Playback will automatically begin. An archived webcast of the call will also be available in the Investor Relations section of the Company’s website for a period of time.

About Sensus Healthcare, Inc.

Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

For more information, visit www.sensushealthcare.com.

Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com

# # #


FAQ

When is the Sensus Healthcare conference call for Q1 2022 results?

The conference call is scheduled for May 5, 2022, at 4:30 p.m. Eastern time.

How can I access the Sensus Healthcare conference call?

You can access the conference call by dialing 888-390-3967 (U.S. Toll Free) or 862-298-0702 (International), or through a live webcast available on the company's website.

What is the focus of the Sensus Healthcare conference call?

The call will discuss the financial results for Q1 2022 and provide a business update on recent and upcoming milestones.

What technology does Sensus Healthcare specialize in?

Sensus Healthcare specializes in non-invasive treatments using low-energy X-ray technology for oncological and non-oncological conditions.